Seeking Alpha

MAP Pharmaceuticals (MAPP -1.2%) intends to refile its new-drug application for its Levadex...

MAP Pharmaceuticals (MAPP -1.2%) intends to refile its new-drug application for its Levadex migraine treatment later this year after meeting with the FDA, which had expressed concerns about manufacturing problems. MAP believes these problems have been resolved and it won't need to carry out new studies. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|